InvestorsHub Logo
Followers 45
Posts 7008
Boards Moderated 0
Alias Born 02/24/2004

Re: realfast95 post# 6000

Saturday, 03/11/2017 10:27:17 AM

Saturday, March 11, 2017 10:27:17 AM

Post# of 8023
Regenerative advanced therapies are eligible for priority review and accelerated approval. It’s our hope that by investigating alternative regulatory paths for ixmyelocel-T will increase the likelihood of accessing the non-dilutive means to commercialize the program. So in summary, we have built a strong foundation for our next phase of growth.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VCEL News